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Background: The visceral adiposity index (VAI) is a newly-derived measure of visceral adiposity with well-validated
predictive power for cardiovascular (CV) outcomes in the general population. However, this predictability has not
been investigated in hemodialysis patients, and whether VAI is superior to waist circumference (WC) and waist-to-height
ratio (WHtR) in predicting CV outcomes and survival in hemodialysis patients remains unknown.
Methods: We performed a prospective study including 464 prevalent hemodialysis patients. The composite outcome
was the occurrence of death and CV events during follow-up. Using multivariate Cox regression analysis, VAI, WC and
WHtR were tested for the predictive power of outcomes. To evaluate the predictive performance of the VAI, WC and
WHtR, time-dependent receiver operating characteristic curve (ROC) analysis was performed.
Results: VAI, WC and WHtR positively correlated with each other. Patients with a higher VAI (tertile 3 vs. tertile 1,
adjusted hazard ratio (HR), 1.65; 95% confidence interval (CI), 1.12-2.42; tertile 2 vs. tertile 1, adjusted HR, 1.52; 95% CI,
1.1-2.18) had more composite outcomes. VAI had a similar predictive power of all-cause mortality to WC and WHtR, but
superior predictive power of composite and CV outcomes to WC when analyzed by a stepwise forward likelihood ratio
test. In time-dependent ROC analysis, VAI, WC and WHtR showed similar predictive performance for outcomes.
Conclusion: VAI is an optimal method to measure visceral adiposity to assess long-term CV outcomes and all-cause
mortality in prevalent hemodialysis patients. VAI may provide a superior predictive power of CV outcomes to WC and
WHtR.
Trial registration: ClinicalTrials.gov NCT01457625
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Visceral adiposity is associated with abnormal lipid metab-
olism, pro-inflammatory activity and insulin resistance in
both the general population [1] and dialysis patients [2,3].
Increased visceral adiposity can lead to incident diabetes
mellitus (DM) and atherosclerosis in the general popula-
tion [1,4], and protein-energy wasting in dialysis patients* Correspondence: taan70@yahoo.com.tw
1Department of Internal Medicine, Far Eastern Memorial Hospital, Division of
Nephrology, #21 Nan-Ya South Rd, Section 2, Banciao District, New Taipei City,
Taiwan
2Division of Nephrology, Department of Internal Medicine, National Taiwan
University Hospital and National Taiwan University College of Medicine,
Taipei, Taiwan
Full list of author information is available at the end of the article
© 2014 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[3,5]. It can also lead to cardiovascular (CV) events and
mortality [3,4,6,7]. The linkage between dysfunctional vis-
ceral adiposity and CV disease has been proven; however,
the best way to measure visceral adiposity in chronic
kidney disease (CKD) and dialysis patients remains in-
conclusive [8]. Waist circumference (WC) [9-13] and
waist-to-height ratio (WHtR) [12-14] are commonly
used in dialysis patients to assess visceral fat, and the
predictability of mortality in hemodialysis (HD) patients
further strengthens the role of WC [10]. Nevertheless,
the predictive power of WC on all-cause mortality and car-
diac death in dialysis patients depends on the body mass
index (BMI) [10], and it has recently been reported to be
affected by the interaction between WC and triglyceridestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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measures of fat mass such as computed tomography [17]
and dual energy X-ray absorptiometry [18] are precise and
reliable, however, they also are extremely costly and com-
plicated to perform in CKD and dialysis patients.
Recently, a newly-derived anthropometric measure of
obesity, the visceral adiposity index (VAI),a sex-specific
index based on WC, BMI, TG, and high density lipopro-
tein cholesterol (HDL-C), has been shown to be an indica-
tor of visceral adipose functionality [19]. It has also been
strongly associated with cardiometabolic risks and the
prediction of CV outcomes, including coronary artery dis-
ease and cerebrovascular disease in the general population
[19-21]. However, whether VAI provides superior predict-
ive power for CV outcomes and survival to WC and
WHtR remains inconclusive. One landmark study showed
that the VAI was better than BMI and WC in the predic-
tion of CV events [19], however, a large-scale population-
based study showed that the VAI is less predictive of
incident CV disease than other simple anthropometric
measures, such as WC or WHtR [22]. In addition, the
utility and the significance of the VAI in dialysis patients
have yet to be investigated.
The aim of this prospective study was to investigate
whether the VAI is a useful tool to assess CV complica-
tions and survival, and to test whether the VAI has su-
perior predictive power of outcomes compared to the
commonly used anthropometric measures of visceral
adiposity in prevalent HD patients.
Methods and procedures
Subjects and patients
This is a prospective, observational study performed in
two patient cohorts. The first cohort was composed of
370 prevalent patients undergoing maintenance HD
[mean age 60 ± 12 years; 162 females; median HD vintage
4.1 years (range: 0.8-19.5 years)]. Information on these pa-
tients has been described elsewhere in more detail [23,24].
Among these 370 patients, 347 had complete data on
WC, BMI, lipid profiles and high sensitive C-reactive pro-
tein (hs-CRP). The second cohort was composed of 216
prevalent HD patients [mean age: 60 ± 12 years; 103 fe-
males; median HD vintage 6.1 years (range: 0.6-25.5 years)]
[25]. All 216 patients in this cohort had complete data
on WC, BMI, lipid profiles and hs-CRP. The exclusion
criteria for entry into the current study in both cohorts
were: (1) active infection; (2) recent hospitalization
within 3 months; (3) psychotic illness or other communi-
cation problems; (4) active malignancy; (5) aged less than
20 years; and (6) receiving HD for less than 3 months.
There were 99 patients in both the first and second co-
hort, and therefore 464 patients (mean age:60 ± 12 years;
235 females) who received prevalent HD at the Far Eastern
Memorial Hospital, Taiwan, were enrolled from February2007 (the first cohort) to October 2011 (the 1st participant
enrolled in the second cohort) into the analysis. The study
design of the first cohort has been reported in the previ-
ously published articles [23,24,26,27]. In the second co-
hort, all subjects gave written informed consent, and the
local ethics committees of the involved hospitals approved
the study protocol (Far Eastern Memorial Hospital Re-
search Ehics Review Committee, FEMH-IRB-099090-E;
chairman Shih-Hong Huang; Oct. 12, 2010; ClinicalTrials.
gov; NCT01457625; Oct. 20, 2011). The authors confirm
that all ongoing and related trials for these cohorts are
registered.
Measurements of clinical parameters, nutritional and
inflammatory status
The demographic data and concurrent medical history
of CV disease were recorded. WC was measured at the
umbilical level over light clothing, using an un-stretched
tape meter, without any pressure to the body surface.
BMI was calculated as weight (kg) divided by the square
of the height (m2). WHtR was calculated as WC (cm) di-
vided by height (cm). Venous blood was sampled in the
morning after an overnight fast of more than 8 hours
before dialysis.
The nutritional status of the participants was calculated
using the geriatric nutritional risk index (GNRI). This
index is calculated from serum albumin level and body
weight as follows: GNRI = [14.89 × albumin (g/dL)] +
[41.7 × body weight/WLo], where WLo is the ideal body
weight calculated from the Lorentz equation. The GNRI
has been validated in dialysis patients, and a higher GNRI
score indicates better nutritional status [28]. We used the
immuno-nephelometric method with a Tina-quant CRP
(Latex) ultra-sensitive assay (D & P Modular Analyzer,
Roche Diagnostics GmbH, Mannheim, Germany) to
determine high sensitive C-reactive protein (hs-CRP)
levels.
Visceral Adiposity Index (VAI)
VAI is a sex-specific index based on WC, BMI, TG, and
HDL-C, and estimates the visceral adiposity functionality.
The VAI was calculated as follows: (TG and HDL-C were
in mmol/l and WC in cm) [19].
Male VAI ¼ WC= 39:68 þ 1:88  BMIð Þ½ ð Þ
 TG=1:03ð Þ  1:31=HDL−Cð Þ
Female VAI ¼ ðWC= 36:58 þ 1:89  BMIð Þ½ Þ
 TG=0:81ð Þ  1:52=HDL−Cð Þ
Outcomes
The outcomes were a composite of all-cause mortality
and CV events, considered jointly or separately. The CV
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including coronary events (non-fatal myocardial infarct,
unstable angina and coronary re-vascularization), hospi-
talized heart failure, incident hospitalized stroke (either
ischemic or hemorrhagic stroke), and incident peripheral
arterial occlusion disease requiring surgical intervention.
The observation period for outcomes was from February
2007 for the patients in the first cohort, from March
2011 for those in the second cohort, and February 2007
for the 99 patients who were recruited in both cohorts.
Follow-up was censored on the date of the first CV
event, the end of the study (November 1, 2013), the date
of death or undergoing renal transplantation, or at the
time the patients were transferred to other dialysis facil-
ities and were no longer followed up, whichever came
first. Initially, we constructed plots of the VAIs and hazard
ratios (HRs) of the outcomes using the Lowess function.
The results revealed their non-linear relationship, suggest-
ing the need for stratification of the patients into tertiles
according to their VAI scores for outcome analysis. There-
fore, we stratified the patients into tertiles according to
their VAI score VAI tertile 1 represented the patients
who had VAI values within 0.32-1.41, VAI tertile 2 had
VAI values 1.42-3.24, and VAI tertile 3 had VAI values
3.25-31.66. The VAI is a gender-specific index, and
there has been reported to be a remarkable difference
between genders in survival [21,22]. In addition, the
VAI, WC and WHtR have been shown to interact with
nutritional status in predicting mortality [6,11,12,14,29].
Therefore, we performed pre-specified subgroup ana-
lysis (gender and nutritional status) when assessing all-
cause mortality.
Statistical analysis
Continuous data were presented as mean ± SD or median
(interquartile range), and categorical data were reported
as percentages. Differences in baseline characteristics and
biochemical parameters among the patients in tertiles of
VAI were compared by ANOVA for continuous variables
and the chi-square test for categorical variables. The non-
parametric Kruskal-Wallis test was used for non-normally
distributed continuous variables.
Outcome analysis was done with using a Cox propor-
tional hazard model, in which the primary predictor
variable was either VAI tertile or VAI as continuous vari-
able, and the covariates included age, gender, vintage of
HD, presence of DM, hypertension and concurrent CV
disease, hemoglobin, calcium phosphate product, hs-
CRP, intact parathyroid hormone and nutritional status
(GNRI).We also selected WC and WHtR as the primary
predictor variables and repeated the outcome analysis.
We used the “Enter” method to analyze the hazard ratio
of each primary predictor variable in the multivariate
Cox regression model, and in order to differentiate thesuperiority of the predictive power of each primary pre-
dictor variable, we also used the “stepwise forward likeli-
hood ratio test” method to analyze the outcomes in the
multivariate Cox regression model.
To further evaluate and compare the predictive per-
formance of the VAI, WC and WHtR, we used time-
dependent receiver operating characteristic (ROC) curves
for censored data, and the area under the ROC curve
(AUC) as the criterion. The time-dependent ROC curve
estimation was analyzed using open-source statistical soft-
ware R. All other statistical analyses were performed using
SPSS software, version 19.0 (SPSS, Inc., Chicago, IL). A
P value of less than 0.05 was considered to be statistically
significant.
Results
Basic characteristics of all participants and by VAI tertiles
The basic characteristics of all participants are summa-
rized in Table 1. Generally, the patients in VAI tertile 3
had a higher percentage of history of DM, hypertension
and concurrent CV disease. In addition, BMI, WC, WHtR,
lipid profiles, hs-CRP and GNRI levels were higher in the
tertile 3 patients.
Composite outcome, all-cause mortality and cardiovascular
events
During the follow-up period (median 4.2 years, range
0.3-6.8 years), 219 patients reached the composite out-
come; 120 patients died and 162 experienced CV events.
In the 162 patients with CV events, 15 had intracranial
hemorrhage, 48 had ischemic stroke, 70 had coronary
artery disease (either non-fatal acute myocardial infarct
or coronary re-vascularization), 20 had peripheral ar-
terial occlusion disease, and 9 were hospitalized for de-
compensated heart failure.
In the unadjusted Cox regression model, the patients
in VAI tertile 2 (HR, 1.6; 1.13-2.26) and VAI tertile 3
(HR, 2.12; 1.51-2.98) had more composite outcomes. In
addition, the patients in VAI tertile 2 (HR, 1.91; 1.26-2.91)
and VAI tertile 3 (HR, 2.68; 1.78-4.03) also had more
CV outcomes, and the patients in VAI tertile 3 had the
worst all-cause mortality (HR, 1.74; 1.11-2.74). Simi-
larly, WC and WHtR also predicted composite and CV
outcomes; however, WC and WHtR did not predict all-
cause mortality.
In the multivariate adjusted model (Table 2), VAI was
a good predictor of composite and CV outcomes. The
patients in VAI tertile 3 had 65% and 80% higher risk of
having composite and CV outcomes, and the patients in
tertile 2 had 52% and 70% higher risk of composite and
CV outcomes. However, after adjusting for multiple
outcome-related factors, the patients in VAI tertile 3
had a marginally higher risk of mortality (HR, 1.49; 1.0-2.5,
P = 0.06). Similarly, a 10-cm larger WC was associated
Table 1 Baseline characteristics of all patients and patients within VAI tertiles
All patients VAI tertiles P value
Tertile 1 (0.32-1.41) Tertile 2(1.42-3.24) Tertile 3(3.25-31.66)
N = 464 N = 155 N = 155 N = 154
Age (year) 60 ± 12 59 ± 11 57 ± 13 62 ± 11 0.004
Gender (women,%) 51 43 45 64 <0.001
Diabetes mellitus (%) 50 34 47 69 <0.001
Dialysis vintage (years) 3.6 ± 3.7 3.6 ± 3.4 4.0 ± 4.6 3.1 ± 2.8 0.1
History of hypertension (%) 78 70 77 85 0.008
History of previous CVD No. (%) 109 (23) 28 (18) 31 (20) 50 (32) 0.005
Kt/Vurea 1.6 (1.3, 1.7) 1.5(1.4, 1.7) 1.6 (1.4, 1.7) 1.6 (1.4, 1.6) 0.5
Systolic BP (mmHg) 147 ± 30 139 ± 69 147 ± 50 148 ± 78 0.1
Diastolic BP (mmHg) 85 ± 13 85 ± 26 83 ± 15 86 ± 15 0.1
Body height (cm) 160 ± 8 160 ± 8 160 ± 9 159 ± 9 0.1
Body weight (Kg) 58 ± 12 54 ± 10 59 ± 12 62 ± 13 <0.001
BMI (Kg.m−2) 22.7 ± 3.7 21 ± 2.9 22.7 ± 3.3 24.3 ± 4.0 <0.001
Waist circumference (cm) 84.9 ± 11.3 79.3 ± 8.8 85.7 ± 10.5 89.7 ± 11.9 <0.001
VAI 2.17 (1.17,4.12) 0.9(0.69,1.17) 2.19(1.76, 2.71) 5.12(4.12, 7.11) <0.001
WHtR 0.53 ± 0.07 0.50 ± 0.05 0.53 ± 0.06 0.57 ± 0.07 <0.01
Laboratory data
Hemoglobin (g/dL) 11.0 ± 1.6 11.1 ± 1.5 11.1 ± 1.6 10.8 ± 1.6 0.1
K (mmol/L) 4.8 ± 0.8 4.9 ± 0.8 4.8 ± 0.8 4.7 ± 0.8 0.1
Ca (mg/dL); corrected 9.2 (8.8, 9.5) 9.0 (8.7, 9.4) 9.2 (8.8, 9.5) 9.3 (8.9, 9.8) <0.001
P (mg/dL) 5.1 (4.3, 6.2) 5.0 (4.5, 6.2) 5.4 (4.2, 6.4) 5.0 (4.1, 6.0) 0.2
CaxP 47 (38, 56) 45 (39, 56) 49 (39, 59) 47 (38, 56) 0.4
T-CHO (mg/dL) 171 (145,200) 157 (137,192) 161(139, 192) 186(160,211) <0.001
TG (mg/dL) 135 (92,212) 78 (62,98) 135(116,168) 256(193,321) <0.001
LDL-C (mg/dL) 89 (67, 115) 81 (66, 108) 89 (68, 116) 97 (68, 118) 0.08
HDL-C (mg/dL) 46 (36, 57) 58 (49, 74) 45(37, 53) 36 (29, 42) <0.001
iPTH (pg/mL) 234 (118, 438) 257 (131, 513) 238 (131, 423) 198(91, 412) 0.08
hs-CRP (mg/L) 3.4 (1.2, 8.2) 2.0 (0.8, 5.4) 4.1 (1.2, 10.1) 4.6 (2.2, 10.1) <0.001
Albumin (g/L) 4.1 ± 0.4 4.1 ± 0.4 4.1 ± 0.4 4.0 ± 0.4 0.06
GNRI 103.3 ± 9.7 100.9 ± 8.5 103.6 ± 8.8 105.6 ± 11.0 <0.001
Medications (%)
ESA 94 93 93 95 0.1
Statins 23 24 22 20 0.1
Anti-hypertensive agents 53 51 51 55 0.2
Abbreviations: VAI visceral adiposity index, CVD cardiovascular disease, BP blood pressure, BMI body mass index, WHtR waist-to-height ratio, K potassium, Ca calcium,
P phosphorus, CaxP calcium phosphate product, T-CHO total cholesterol, TG triglyceride, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein
cholesterol, iPTH intact parathyroid hormone, hs-CRP high-sensitive C-reactive protein, GNRI geriatric nutritional risk index, ESA erythropoiesis stimulating
agents, Statins, HMG-CoA reductase inhibitors.
Note: Conversion factors for units: hemoglobin in g/dL to g/L, ×10; serum calcium in mg/dL to mmol/L, ×0.2495; serum phosphate in mg/dL to mmol/L, ×0.3229;
serum T-CHO in mg/dL to mmol/L,×0.02586;serum LDL-C in mg/dL to mmol/L, ×0.02586; serum TG in mg/dL to mmol/L, ×0.01129; serum albumin in g/dL to g/L, ×10.
No conversion necessary for serum iPTH in pg/mL and ng/L; serum potassium in mEq/L and mmol/L.
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in WHtR was associated with 5% and 6% higher risk for
composite and CV outcomes after multivariate adjust-
ments. However, WC and WHtR did not predict all-cause
mortality after adjustments (Table 2).The predictive performance of the VAI, WC and WHtR on
the composite outcomes, cardiovascular events and
all-cause mortality
We used the stepwise forward likelihood ratio method
in the adjusted multivariate model (Table 3), and found
Table 2 VAI, WC, WHtR and baseline factors associated with outcomes in all participants analyzed by Cox
proportional-hazards regression model with multivariate adjustments (with the Enter method)
Variables Composite outcome Cardiovascular outcome All-cause mortality
Adjusted HR (95% CI)§ P Adjusted HR (95% CI)§ P Adjusted HR (95% CI)§ P
VAI (tertile 2 vs. tertile 1) 1.52 (1.1-2.18) 0.02 1.70 (1.1-2.61) 0.02 1.33(0.81-2.16) 0.3
VAI (tertile 3 vs. tertile 1) 1.65 (1.12-2.42) 0.01 1.80 (1.1-2.8) 0.01 1.49(1.0-2.5) 0.06
VAI (every 1 unit increase) 1.38 (1.08-1.98) 0.002 1.4 (1.11-1.89) 0.01 1.21 (0.99-1.29) 0.4
WC (every 10 cm increase) 1.29 (1.08-1.54) 0.005 1.36 (1.1-1.67) 0.004 1.11(0.88-1.4) 0.4
WHtR (every 0.01 unit increase) 1.05(1.02-1.08) 0.003 1.06(1.02-1.09) 0.003 1.02(0.98-1.06) 0.4
Demographic data
With DM 2.2 (1.63-3.0) <0.001 2.44 (1.5-3.5) <0.001 2.05(1.36-3.08) 0.001
With CV disease history 1.48 (1.1-2.0) 0.01 1.83 (1.31-2.57) <0.001 1.37(0.92-2.06) 0.1
With HTN 1.13 (0.77-1.67) 0.5 1.31 (0.82-2.1) 0.3 1.01(0.5-1.31) 0.4
Age (every 10 years increase) 1.38 (1.24-1.52) <0.001 1.28 (1.1-1.4) 0.001 1.57(1.37-1.77) <0.001
HD vintage (every 1 year increase) 1.02 (0.98-1.06) 0.3 1.03 (0.98-1.08) 0.2 1.01(0.95-1.07) 0.8
Laboratory parameters
hs-CRP 1.05 (0.99-1.12) 0.08 1.04 (0.96-1.12) 0.4 1.1(1.02-1.18) 0.01
Hemoglobin 0.9 (0.82-0.99) 0.05 0.93 (0.83-1.05) 0.3 0.92(0.8-1.05) 0.2
GNRI 0.98 (0.96-0.99) 0.002 0.99 (0.97-1.01) 0.4 0.96(0.94-0.98) <0.001
iPTH 1.0 (0.99-1.01) 0.2 1.0 (0.99-1.02) 0.4 1.0(1.0-1.001) 0.8
CaxP 1.003 (0.99 ~ 1.01) 0.5 1.002(0.99-1.01) 0.7 1.008(0.99-1.07) 0.2
Abbreviations: VAI visceral adiposity index, WC waist circumference, WHtR waist-to-height ratio, HR hazard ratio, CI confidence interval, P P value, DM diabetic
mellitus, CV cardiovascular, HTN hypertension, HD hemodialysis, hs-CRP highly-sensitive C-reactive protein, GNRI geriatric nutritional risk index, iPTH intact
parathyroid hormone, CaxP calcium phosphate product.
§Adjusted for gender, age, HD vintage, presence of DM, HTN and concurrent CV disease, hemoglobin, iPTH, hs-CRP, calcium phosphate product and GNRI levels.
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comes. However, WC and WHtR did not predict com-
posite outcome, CV outcome or all-cause mortality, and
the VAI and WHtR were also not good predictors of all-
cause mortality.Table 3 VAI, WC and WHtR in all participants analyzed by Cox
adjustments (with the stepwise forward likelihood ratio meth
Variables Composite outcome
Adjusted HR (95% CI)§ P
VAI (tertile 2 vs. tertile 1) 1.5 (1.07-2.08) 0.04
VAI (tertile 3 vs. tertile 1) 1.62 (1.22-2.32) 0.04
WC (every 10 cm increase) - 0.4
WHtR (every 0.01 unit increase) - 0.1
Taking VAI as a continuous variable
VAI (every 1 unit increase) 1.4 (1.23-2.25) 0.01
WC (every 10 cm increase) - 0.4
WHtR (every 0.01 unit increase) - 0.1
Abbreviations: VAI visceral adiposity index, WC waist circumference, WHtR waist-to-h
mellitus, CV cardiovascular, HTN hypertension, HD hemodialysis, hs-CRP highly-sensi
parathyroid hormone, CaxP calcium phosphate product.
§Adjusted for gender, age, HD vintage, presence of DM, HTN and concurrent CV dis
-: indicated non-selected in the stepwise likelihood ratio model.Time-dependent ROC analysis of the VAI, WC and WHtR
as predictors of composite outcome, cardiovascular
outcome and all-cause mortality
The AUC for the VAI, WC and WHtR versus outcomes
are shown in Table 4. VAI, WC and WHtR had similarproportional-hazards regression model with multivariate
od)
Cardiovascular outcome All-cause mortality
Adjusted HR (95% CI)§ P Adjusted HR (95% CI)§ P
1.72 (1.13-2.63) 0.01 - 0.8
1.69 (1.11-2.6) 0.02 - 0.4
- 0.3 - 0.1
- 0.2 - 0.2
1.69 (1.3-2.2) 0.01 - 0.4
- 0.3 - 0.1
- 0.2 - 0.2
eight ratio, HR hazard ratio, CI confidence interval, P P value, DM diabetic
tive C-reactive protein, GNRI geriatric nutritional risk index, iPTH intact
ease, hemoglobin, iPTH, hs-CRP, calcium phosphate product and GNRI levels.
Table 4 AUCs of ROC curves for the prediction of composite outcome, CV outcome and all-cause mortality by VAI, WC
and WHtR
VAI WC WHtR P-value (compare WC and VAI) P-value (compare WHtR and VAI)
Composite outcomes
T = 4 years 60.85 ± 2.87 59.26 ± 3.09 59.98 ± 3.07 0.63 0.79
T = 5 years 59.67 ± 2.97 60.69 ± 3.09 60.79 ± 3.08 0.76 0.73
T = 6 years 62.82 ± 3.01 61.83 ± 3.17 62.42 ± 3.14 0.77 0.90
CV outcomes
T = 4 years 63.12 ± 3.06 62.23 ± 3.38 63.26 ± 3.36 0.80 0.97
T = 5 years 61.76 ± 3.16 63.06 ± 3.28 62.97 ± 3.29 0.71 0.73
T = 6 years 65.56 ± 3.15 64.31 ± 3.33 64.65 ± 3.31 0.72 0.79
All-cause mortality
T = 4 years 57.41 ± 3.51 51.87 ± 3.91 51.44 ± 3.78 0.22 0.15
T = 5 years 57.41 ± 3.51 54.74 ± 3.62 54.91 ± 3.56 0.74 0.76
T = 6 years 57.08 ± 3.28 57.56 ± 3.54 58.16 ± 3.49 0.90 0.76
Note: Values are expressed as AUC ± SE (95% confidence interval).
Abbreviations: AUC area under curve, ROC receiver operating characteristic, CV cardiovascular, VAI visceral adiposity index, WC waist circumference,
WHtR waist-to-height ratio.
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lysis at the fourth, fifth and sixth years of follow-up.
Pre-specified subgroup analysis of the impacts of the VAI,
WC, and WHtR on all-cause mortality
In men, the VAI (VAI 3 versus VAI 1, HR, 2.95; 1.3-6.69
and VAI 2 versus VAI 1, HR, 2.25; 1.15-4.39), WC (HR,
1.51; 1.13-2.03, every 10 cm increase) and WHtR (HR,
1.09; 1.03-1.16, every 0.01 unit increase) all predicted
all-cause mortality. However, in women, the VAI, WC
and WHtR did not predict all-cause mortality. The VAI
predicted all-cause mortality in patients with better nu-




































Figure 1 Relationship between visceral adiposity index (VAI) tertiles a
nutritional status. The VAI predicted all-cause mortality in patients with a
nutritional status (GNRI < 103.6). Analysis were adjusted for gender, age, he
cardiovascular disease, hemoglobin, intact parathyroid hormone, high sensworse nutritional status (GNRI < 103.6) (Figure 1). How-
ever, WC did not predict all-cause mortality in either the
patients with better (GNRI ≥ 103.6, HR = 1.12; 0.67-2.45,
every 10 cm increase) or worse (GNRI < 103.6, HR =
1.03; 0.58-2.55) nutritional status. Similarly, WHtR did
not predict all-cause mortality in either patients with
better (HR = 1.06; 0.55-1.7, every 0.01 unit increase) or
worse (HR = 1.01; 0.38-3.55, every 0.01 unit increase)
nutritional status.
Discussion
The main findings of this study are that in prevalent HD





nd all-cause mortality in hemodialysis patients with different
better nutritional status (GNRI≥ 103.6) but not in those with a worse
modialysis vintage, presence of diabetes, hypertension and concurrent
itive C-reactive protein and calcium phosphate product.
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those with a better nutritional status. Moreover, the VAI
might have a better predictive performance on compos-
ite outcome and CV outcome than WC and WHtR in
HD patients.
Abdominal obesity is a crucial factor when predicting
CV complications, and is a major component of the
metabolic syndrome in both the general population and
diabetic patients [7]. In our previous cohort [25] and in
another study [10], nearly 40 ~ 50% of dialysis patients
had abdominal obesity according to the diagnostic criteria
recommended by the US National Cholesterol Education
Programme Adult Treatment Panel III (NCEP ATP III)
guidelines. Associations between abdominal obesity, in-
flammation, atherosclerosis and consequently CV mor-
tality and morbidity have also been reported in both
dialysis [3,5,10,30] and CKD patients [31,32]. Therefore,
it is worthwhile to precisely measure the severity of ab-
dominal obesity in dialysis patients.
In this study, the HD patients with higher abdominal
adiposity as measured by the VAI, had worse lipid profiles,
higher hs-CRP levels (Table 1) and more importantly,
higher CV and composite outcomes. The predictive value
of the VAI for CV complications and cardiometabolic risks
has been validated in the general population [19,21,22]
and in some diseases such as non-alcoholic fatty liver dis-
ease [33], acromegaly [34] and sleep apnea syndrome [35].
To the best of our knowledge, no investigation has ex-
plored the predictive power of the VAI on CV outcomes
and survival in dialysis patients, and that this is the first
study to clearly show that higher VAI values predicted
worse composite outcomes (Table 2).This validation in
HD subjects is worth emphasizing because many import-
ant CV outcomes and survival predictors in the general
population such as BMI and lipid profiles have an inverse
predictive power in dialysis subjects. Therefore, our results
confirm that the VAI is also a reliable tool to assess ab-
dominal adiposity dysfunction in dialysis patients, and to
predict consequent cardiometabolic complications.
WC and WHtR are commonly used as measures of
abdominal adiposity in the general population and dialy-
sis subjects because they are easy to calculate, have been
validated as the gold standard of visceral adiposity mea-
sures, and the correlation with CV outcomes has been
established [8,10,11,14]. However, there are drawbacks
of WC-based assessments of abdominal adiposity. First,
WC represents both visceral adipose tissue and subcuta-
neous adipose tissue, which correspond to different out-
come results [36,37]. Second, WC correlates poorly with
changes in visceral adiposity over time in CKD patients
[38]. Third, although the predictive power of all-cause
mortality and incident CV events in HD patients has
been validated, the predictive power only occurs after
adjusting for BMI, which implies that an interactionbetween WC and BMI explains the outcomes [10] The
same investigator also identified interactions between
WC versus TG levels and WC versus adipokine levels
when assessing all-cause and CV mortality [15,16] in
HD patients. Therefore, WC may be an imperfect meas-
ure of visceral adiposity in dialysis patients, and there-
fore other tools to measure visceral adiposity should be
carefully considered. The VAI is also a WC-based meas-
ure, however it is adjusted for BMI and interactions with
TG and HDL-C. Therefore, the VAI may be a better tool
for measuring visceral adiposity and in assessing its im-
pacts on CV outcomes and survival. In our multivariate
Cox regression results, only VAI tertile 3 predicted a
marginally higher risk of mortality, whereas WC and
WHtR did not (Table 2). Further, when we applied the
stepwise forward likelihood ratio method, the VAI had a
better predictive performance than WC and WHtR
(Table 3). In time-dependent ROC analysis, the VAI had
a similar AUC to those of WC and WHtR in the pre-
diction of all outcomes (Table 4). These results further
strengthen the hypothesis that the VAI may be a su-
perior predictor, or at least, an equal predictor com-
pared with WC and WHtR when assessing the impact
of visceral adiposity dysfunction on CV outcomes and
mortality.
Over-nutrition leads to abdominal obesity and conse-
quently incident diabetes and CV events [4]. In addition,
nutritional status has been shown to be a determinant of
survival in dialysis patients [39]. In our results, the pa-
tients with higher VAI values had better nutritional sta-
tus (Table 1), and therefore we presumed an interaction
between the VAI and nutritional status when assessing
the predictive power for all-cause mortality. As shown in
Figure 1, higher VAI values predicted a higher risk of
mortality in the HD patients with better nutritional sta-
tus (GNRI ≥ 103.6), but not in those with a worse nutri-
tional status. We hypothesize that dialysis patients with
a better nutritional status are exempt from the impacts
of malnutrition and protein-energy wasting on overall
survival, and therefore the impact of visceral adiposity
on all-cause mortality becomes pronounced. In contrast,
in patients with a relatively poor nutritional status,
higher visceral adiposity predicts a higher likelihood of
survival, a phenomenon called obese sarcopenia, which
has been explored in dialysis patients [5,6]. Hence, the
impact of the VAI on all-cause mortality would be less
in this circumstance.
The strengths of this study are its prospective nature,
optimal observational period, full adjustment for mul-
tiple CV and survival factors in outcome analysis, and
extended outcome analysis including both CV complica-
tions and all-cause mortality. However, there are some
limitations to this study. First, we did not perform other
machine-based assessments of visceral adiposity such as
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ometry to validate the role of the VAI in measuring vis-
ceral adiposity in HD patients. Second, the annual
mortality rate in this study was similar to our previously
report [26] and to another study from Taiwan [40] in
dialysis patients, but lower than reported in Western
counties [10]. Furthermore, 34 patients (6.9%) in this
study were censored because they were transferred to
other dialysis facilities and were no longer followed up,
and therefore the annual mortality rate may have been
underestimated and the results of the consequent Cox
survival analysis may be inaccurate. Third, the present
study was based in a single center cohort in Taiwan, and
therefore further investigations in multiple centers or in
different ethnicities are warranted.
In summary, our results suggest that the VAI positively
correlates with WC and WHtR and is an optimal
method to measure visceral adiposity to assess long-
term CV outcomes and all-cause mortality in prevalent
HD patients. In HD patients with a good nutritional sta-
tus, the VAI has a superior predictive power for all-
cause mortality than WC or WHtR.
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